Krukovine Suppresses KRAS-Mutated Lung Cancer Cell Growth and Proliferation by Inhibiting the RAF-ERK Pathway and Inactivating AKT Pathway

PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives

(2016) Vivek Asati et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer

(2016) P. Tomasini et al.   ONCOLOGIST

Cissampelos sympodialis Eichl. (Menispermaceae), a medicinal plant, presents antimotility and antidiarrheal activity in vivo

(2015) Igor Rafael Praxedes de Sales et al.   BMC Complementary and Alternative Medicine

mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer

(2015) Feng Wei et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Dragging Ras Back in the Ring

(2014) Andrew G. Stephen et al.   CANCER CELL

MEK inhibition in non-small cell lung cancer

(2014) Thomas E. Stinchcombe et al.   LUNG CANCER

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

The Role of STAT3 in Non-Small Cell Lung Cancer

(2014) Daijiro Harada et al.   Cancers

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC

(2013) Susan Heavey et al.   CANCER TREATMENT REVIEWS

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

(2013) Julien Mazières et al.   JOURNAL OF CLINICAL ONCOLOGY

Abstract 23: Sensitivity ofEGFRexon 20 insertion mutations to EGFR inhibitors is determined by their location within the tyrosine kinase domain of EGFR

(2012) Hiroyuki Yasuda et al.   CANCER RESEARCH

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

(2012) A. B. Turke et al.   CANCER RESEARCH

A Comprehensive Survey of Ras Mutations in Cancer

(2012) I. A. Prior et al.   CANCER RESEARCH

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

(2012) J. M. Spoerke et al.   CLINICAL CANCER RESEARCH

Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy

(2012) J. S. Logue et al.   GENES & DEVELOPMENT

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu

(2012) J. De Grève et al.   LUNG CANCER

Comprehensive genomic characterization of squamous cell lung cancers

(2012)   NATURE

Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer

(2011) D. Gioeli et al.   MOLECULAR CANCER THERAPEUTICS

Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo

(2010) Jieru Meng et al.   PLoS One

Targeting the RAF–MEK–ERK pathway in cancer therapy

(2009) Clara Montagut et al.   CANCER LETTERS

SnapShot: Ras Signaling

(2008) Megan Cully et al.   CELL

The Role of Targeting Mammalian Target of Rapamycin in Lung Cancer

(2008) Sumanta Kumar Pal et al.   Clinical Lung Cancer